Natural Capsules Ltd
Incorporated in 1993, Natural Capsules manufactures Capsules and Steroidal APIs and their Intermediates and Derivatives[1]
- Market Cap ₹ 196 Cr.
- Current Price ₹ 190
- High / Low ₹ 299 / 164
- Stock P/E
- Book Value ₹ 237
- Dividend Yield 0.00 %
- ROCE 2.67 %
- ROE 0.28 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.80 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 5.07% over last 3 years.
- Contingent liabilities of Rs.70.8 Cr.
- Company might be capitalizing the interest cost
- Promoter holding has decreased over last 3 years: -5.30%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 55 | 60 | 62 | 80 | 135 | 170 | 155 | 169 | 180 | |
| 49 | 55 | 56 | 68 | 110 | 135 | 134 | 151 | 172 | |
| Operating Profit | 6 | 5 | 5 | 11 | 26 | 35 | 20 | 18 | 8 |
| OPM % | 10% | 8% | 9% | 14% | 19% | 21% | 13% | 10% | 4% |
| 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | |
| Interest | 0 | 1 | 1 | 1 | 2 | 4 | 5 | 7 | 8 |
| Depreciation | 4 | 3 | 4 | 4 | 5 | 7 | 9 | 9 | 13 |
| Profit before tax | 2 | 2 | 1 | 9 | 19 | 25 | 8 | 3 | -12 |
| Tax % | 34% | 7% | 38% | 24% | 28% | 26% | 31% | 78% | |
| 1 | 2 | 1 | 7 | 14 | 18 | 6 | 1 | -12 | |
| EPS in Rs | 1.19 | 2.06 | 0.92 | 7.43 | 14.96 | 20.02 | 5.95 | 0.60 | -11.55 |
| Dividend Payout % | 56% | 32% | 43% | 9% | 5% | 5% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | 8% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | -65% |
| TTM: | -650% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 24% |
| 3 Years: | -28% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 5% |
| Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 7 | 9 | 9 | 10 | 10 |
| Reserves | 48 | 49 | 49 | 56 | 76 | 114 | 194 | 223 | 235 |
| 0 | 5 | 6 | 10 | 53 | 97 | 109 | 105 | 112 | |
| 19 | 14 | 14 | 26 | 29 | 70 | 64 | 81 | 62 | |
| Total Liabilities | 73 | 75 | 76 | 99 | 165 | 290 | 377 | 419 | 420 |
| 22 | 24 | 24 | 38 | 66 | 97 | 103 | 284 | 281 | |
| CWIP | 1 | 2 | 2 | 7 | 20 | 88 | 144 | 0 | 1 |
| Investments | 5 | 5 | 6 | 0 | 0 | 0 | 3 | 3 | 3 |
| 45 | 43 | 45 | 54 | 79 | 105 | 127 | 133 | 135 | |
| Total Assets | 73 | 75 | 76 | 99 | 165 | 290 | 377 | 419 | 420 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| 5 | 2 | 7 | 6 | -1 | 17 | -8 | 27 | |
| -1 | -7 | -6 | -9 | -46 | -105 | -73 | -44 | |
| -4 | 4 | -1 | 3 | 48 | 87 | 82 | 16 | |
| Net Cash Flow | 0 | -1 | 0 | -0 | 1 | 0 | 1 | -2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 208 | 197 | 180 | 123 | 71 | 112 | 129 | 134 |
| Inventory Days | 149 | 87 | 89 | 82 | 34 | 45 | 88 | 109 |
| Days Payable | 185 | 114 | 91 | 157 | 98 | 127 | 141 | 166 |
| Cash Conversion Cycle | 172 | 170 | 179 | 48 | 7 | 30 | 76 | 78 |
| Working Capital Days | 186 | 143 | 121 | 75 | 73 | 61 | 80 | 53 |
| ROCE % | 5% | 4% | 11% | 21% | 15% | 5% | 3% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Dec
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
19 Nov - Q2 revenue Rs45.80cr, net loss Rs6.99cr; FY26 guidance trimmed to ~Rs225cr; API ramp-up issues, US tariff impact.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
17 Nov - Audio recording of investor conference call on November 17, 2025 posted on company website.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Nov - Newspaper Publication regarding Unaudited Standalone & Consolidated Financial Results for the Quarter and half year ended September 30,2025
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
14 Nov - Q2 revenue ₹45.80Cr, PAT loss ₹6.99Cr; H1 revenue ₹91.01Cr, PAT loss ₹12.57Cr; tariffs, API delays.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Nov 2025Transcript PPT
-
Aug 2025TranscriptAI SummaryPPT
-
Jun 2025TranscriptPPT
-
Jun 2025Transcript PPT REC
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024Transcript PPT REC
-
May 2024Transcript PPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptPPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptAI SummaryPPT
-
Jun 2023Transcript PPT
-
Feb 2023TranscriptAI SummaryPPT
-
Oct 2022TranscriptAI SummaryPPT
-
Aug 2022TranscriptAI SummaryPPT
-
May 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
Business Overview:[1][2][3]
NCL is a WHO-GMP certified and ISO 9001, ISO 140001 compliance manufacturer of printed and unprinted hard two-piece Gelatin and Cellulose (HPMC : non-animal alternative) capsules for pharmaceutical and dietary supplement industries in various sizes of 00, 0el, 0, 1, 2, 3 & 4. Apart from this, NCL has forayed into API manufacturing with complex high-end patented technology developed in-house, under its subsidiary company Natural Biogenex Private Limited.